Zentek Ltd. (NASDAQ:ZTEK) Sees Significant Decrease in Short Interest

Zentek Ltd. (NASDAQ:ZTEK) was the recipient of a significant decline in short interest in the month of October. As of October 15th, there was short interest totaling 115,200 shares, a decline of 26.2% from the September 30th total of 156,100 shares. Based on an average trading volume of 316,600 shares, the short-interest ratio is presently 0.4 days. Approximately 0.1% of the company’s shares are short sold. Approximately 0.1% of the company’s shares are short sold. Based on an average trading volume of 316,600 shares, the short-interest ratio is presently 0.4 days.

Analyst Ratings Changes

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Zentek in a research report on Wednesday, October 8th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock presently has an average rating of “Sell”.

Zentek Stock Performance

Shares of NASDAQ ZTEK opened at $0.83 on Monday. The firm has a market cap of $86.54 million, a P/E ratio of -16.50 and a beta of 0.90. The company has a debt-to-equity ratio of 0.12, a quick ratio of 1.30 and a current ratio of 1.62. The stock has a fifty day moving average price of $0.83 and a two-hundred day moving average price of $1.08. Zentek has a 1 year low of $0.62 and a 1 year high of $1.84.

Zentek (NASDAQ:ZTEK) last released its quarterly earnings data on Thursday, August 14th. The company reported ($0.01) earnings per share for the quarter. The company had revenue of $0.04 million for the quarter. Zentek had a negative return on equity of 55.41% and a negative net margin of 981.17%.

Zentek Company Profile

Zentek Ltd., together with its subsidiaries, engages in the research and development of graphene and related nanomaterials in Canada. The company develops graphene-based antimicrobial coating under the ZenGUARD brand, surgical masks, HVAC filters, personal protective equipment, rapid detection point of care diagnostics tests, and pharmaceutical products based on graphene-based compounds.